semaglutide cardiovascular outcomes study news Weight loss and disease risk of semaglutide: a one-year multicentered Oral Semaglutide and Cardiovascular Outcomes

Fatty liver disease affects an estimated 25% of the global population and has no approved medication specifically for the condition in most countries

The pivotal STEP 1 trial, published in The New England Journal of Medicine in February, included 1,961 adults without diabetes who had obesity or overweight with a weight-related comorbid condition

Denmark and Sweden lead in both awareness and use of GLP-1 treatments such as Ozempic and Wegovy

In the Israeli market, there are currently only two drugs that are taken orally and are used to treat obesity

Contents About MIC Injections MIC injections can help your body reduce stubborn subcutaneous fat , a type of fat that sits beneath the skin and protects your organs from injury

The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors